Ginkgo Bioworks Holdings Inc DNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DNA is a good fit for your portfolio.
News
-
Il Granaio delle Idee and Ginkgo Bioworks Announce Strategic Collaboration to Optimize Sourdough Strains for Bakery Products
-
Ginkgo Bioworks Announces Acquisition of AgBiome's Platform Assets
-
Ginkgo Bioworks Previews Today's Annual Ferment Conference, Announces "Lab Data as a Service"
-
Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain
-
Ginkgo Bioworks Awarded Grant for AI-enabled Forecasting of Measles Outbreaks
-
IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service
-
Ginkgo Bioworks to Host 5th Annual Ferment Conference
-
Prozomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API Manufacturing
Trading Information
- Previous Close Price
- $0.92
- Day Range
- $0.85–0.94
- 52-Week Range
- $0.85–2.55
- Bid/Ask
- $0.86 / $0.90
- Market Cap
- $1.86 Bil
- Volume/Avg
- 38.9 Mil / 23.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.69
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,218
- Website
- https://www.ginkgobioworks.com
Comparables
Valuation
|
Metric
|
DNA
|
EQRX
|
CGEM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.58 | 0.97 | 1.71 |
Price/Sales | 6.69 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DNA
|
EQRX
|
CGEM
|
|---|---|---|---|
Quick Ratio | 5.96 | 18.43 | 16.60 |
Current Ratio | 6.11 | 18.78 | 17.07 |
Interest Coverage | −10,215.74 | — | — |
Quick Ratio
DNA
EQRX
CGEM
Profitability
|
Metric
|
DNA
|
EQRX
|
CGEM
|
|---|---|---|---|
Return on Assets (Normalized) | −20.50% | −15.72% | −24.60% |
Return on Equity (Normalized) | −31.17% | −16.71% | −25.95% |
Return on Invested Capital (Normalized) | −27.79% | −21.31% | −29.67% |
Return on Assets
DNA
EQRX
CGEM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tynhzhdy | Fzr | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ndkssdmly | Cndvsw | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zfnxldvs | Gmcnh | $98.1 Bil | |
MRNA
| Moderna Inc | Qbxxpzws | Jxzzy | $38.8 Bil | |
ARGX
| argenx SE ADR | Pfkmdvkh | Mwd | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Qbqdsrdmp | Vmpy | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bttlhztd | Qwytz | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wbjxynrc | Sdxgk | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kkdmcgbrf | Cvtrgrr | $12.5 Bil | |
INCY
| Incyte Corp | Nymgsrht | Fgpcvsv | $11.9 Bil |